Arlo-cel Registrational Study Meets Response Endpoints

Evidence Company release · Discovery September 8, 2026 · Note Meaningful update to the September 4 InSilens report on the published Phase I study · Importance 5/5 · Direction Positive Summary Bristol Myers Squibb said the registrational Phase II QUINTESSENTIAL study of arlocabtagene autoleucel met…